Breaking News Instant updates and real-time market news.

BMRN

BioMarin

$83.62

-1.38 (-1.62%)

, ESALY

Eisai

$57.49

-0.15 (-0.26%)

04:55
12/05/17
12/05
04:55
12/05/17
04:55

American Epilepsy Society to hold annual meeting

AES Annual Meeting 2017 is being held in Washington, D.C. on December 1-5.

BMRN

BioMarin

$83.62

-1.38 (-1.62%)

ESALY

Eisai

$57.49

-0.15 (-0.26%)

GWPH

GW Pharmaceuticals

$115.44

-7.51 (-6.11%)

IART

Integra LifeSciences

$48.26

-0.83 (-1.69%)

NVTA

Invitae

$8.56

-0.14 (-1.61%)

MNK

Mallinckrodt

$21.96

0.14 (0.64%)

MDT

Medtronic

$79.87

-1.4 (-1.72%)

RICOY

Ricoh Company, Ltd.

SUPN

Supernus

$37.15

-0.05 (-0.13%)

WTKWY

Wolters Kluwer

$51.69

0.17 (0.33%)

ZBH

Zimmer Biomet

$114.82

0.25 (0.22%)

  • 05

    Dec

  • 06

    Dec

  • 12

    Dec

  • 14

    Dec

  • 08

    Jan

  • 18

    Jan

  • 28

    Feb

  • 25

    Mar

BMRN BioMarin
$83.62

-1.38 (-1.62%)

10/18/17
PIPR
10/18/17
NO CHANGE
Target $113
PIPR
Overweight
Piper says BioMarin weakness after 'positive' R&D day a buying opportunity
Piper Jaffray analyst Christopher Raymond said the number one question he is receiving following BioMarin's "decidedly positive" R&D day has been "why is the stock down?" He suggests it may be a "sell-the-news" reaction to the event and recommends buying on today's weakness, given that he believes "significant meaningful progress" was communicated during the event. Raymond keeps an Overweight rating and $113 price target on BioMarin shares, which are down 5% to $89 in late day trading.
10/19/17
LEER
10/19/17
NO CHANGE
Target $142
LEER
Outperform
BioMarin price target raised to $142 from $136 at Leerink
Leerink analyst Joseph Schwartz raised his price target for BioMarin to $142 from $136 after management provided encouraging updates on key programs BMN270, BMN111/vosoritide, BMN165/pegvaliase, BMN250, unveiled a new program BMN290 for Friedreich's Ataxia, and discussed weak sales in Brazil leading to lower Q3 revenues. The analyst also increased his PoS for pegvaliase to 85% from 60%. He reiterates an Outperform rating on the shares.
10/19/17
FBCO
10/19/17
NO CHANGE
Target $124
FBCO
Outperform
BioMarin price target raised to $124 from $114 at Credit Suisse
Credit Suisse analyst Alethia Young raised her price target for BioMarin to $124 from $114 as she believes there is a higher chance of success for hemophilia A gene therapy. The analyst reiterates an Outperform rating on the shares.
10/06/17
GSCO
10/06/17
INITIATION
Target $124
GSCO
Buy
BioMarin resumed with a Buy at Goldman Sachs
Goldman analyst Salveen Richter resumed coverage on BioMarin with a Buy and $124 price target.
ESALY Eisai
$57.49

-0.15 (-0.26%)

02/15/17
LEER
02/15/17
NO CHANGE
LEER
Biogen outlook intact despite Merck study suspension, says Leerink
Leerink analyst Geoffrey Porges notes that Merck (MRK) announced the suspension of the Phase 2/3 EPOCH trial of verubecestat in mild-to-moderate Alzheimer's patients for lack of efficacy, which was one of the most important catalysts for the field this year and a significant overhang for Biogen (BIIB) and other companies. While the failure had been widely anticipated in this study, the analyst believes this result does not read over to the outlook for Biogen's ongoing pivotal trials with aducanumab, or with its partner, Eisai's (ESALY) BACE inhibitor, elenbecestat.
01/05/17
JMPS
01/05/17
NO CHANGE
JMPS
Market Perform
JMP Securities views Arena amended agreement with Eisai 'favorably'
JMP Securities analyst Jason Butler says Arena Pharmaceuticals' (ARNA) amended agreement with Eisai (ESALY) reduces resource and capital constraints on the company while maintaining "attractive" long-term upside from Belviq success. The analyst notes that Eisai will now have full global development and marketing rights to Belviq in exchange for lowering Arena's royalties and cost contributions, which he views "favorably" as the commercial potential for it remains limited. Furthermore, the new agreement allows Arena to further focus its energies and resources in its Phase 2 pipeline assets, Butler adds. He reiterates a Market Perform on Arena Pharmaceuticals' shares.
GWPH GW Pharmaceuticals
$115.44

-7.51 (-6.11%)

09/29/17
WBLR
09/29/17
UPGRADE
WBLR
Outperform
William Blair calls Zogenix data best to date in upgrade to Outperform
William Blair analyst Tim Lugo earlier today upgraded Zogenix (ZGNX) to Outperform from Market Perform saying the company's Dravet data is the best to date. Zogenix's ZX008 looks superior to GW Pharmaceuticals' (GWPH) cannabinoid candidate, Epidiolex, Lugo told investors in a research note. Shares of Zogenix are up 179% to $35.88 after the company this morning announced positive top-line results from its first Phase 3 trial for ZX008 for the treatment of Dravet syndrome. GW Pharmaceuticals is down 8% to $102.79 in afternoon trading.
11/21/17
CANT
11/21/17
NO CHANGE
Target $208
CANT
Overweight
Abstracts put GW's drug-drug interaction issue to rest, says Cantor
Cantor Fitzgerald analyst Elemer Piros says the American Epilepsy Society published last night 20 abstracts detailing the safety/efficacy of GW Pharmaceuticals' Epidiolex in a multitude of controlled trials and refractory epilepsy indications. GW and collaborators "finally laid the somewhat common concern to rest: does the drug work partly or solely due to a boosting effect on another anti-epileptic drug commonly used, Clobazam?" Piros tells investors in a research note. He believes the answer is "partly." The bear thesis of Epidiolex working "solely" through boosting Clobazam's efficacy has been qualitatively debunked by management before, and now there are numbers to back it up, the analyst adds. He expects a potential approval for Epidiolex in April 2018. Piros has an Overweight rating on GW Pharmaceuticals with a $208 price target. The stock in premarket trading is up $5.23 to $120.00.
11/20/17
STFL
11/20/17
NO CHANGE
Target $55
STFL
Buy
Physicians expressed excitement for Zogenix epilepsy treatment, says Stifel
After hosting a panel to discuss new developments for rare epileptic conditions, Stifel analyst Annabel Samimy noted that physicians in the space said they believed there was a place for both Zogenix's (ZGNX) fenfluramine and GW Pharmaceuticals' (GWPH) Epidiolex, the two most advanced treatments for Dravet Syndrome and Lennox-Gastaut Syndrome. Excitement for their introductions was "palpable, particularly for fenfluramine," added Samimy, who has a Buy rating and $55 price target on Zogenix and does not cover GW Pharmaceuticals.
10/03/17
MZHO
10/03/17
NO CHANGE
Target $51
MZHO
Buy
Zogenix price target raised to $51 from $28 at Mizuho
Mizuho analyst Difei Yang raised his price target for Zogenix (ZGNX) to $51 from $28 after it announced positive topline data for its pivotal phase III trial of ZX008 in Dravet Syndrome - Study 1. The analyst notes study 1 met its primary endpoint, with topline results indicating a clear dose response, efficacy appears better than GW Pharma's (GWPH) Epidiolex, and mechanism of action involving Sig-1R receptor could explain the higher specificity of ZX-008. Yang argues that these findings may allow ZX-008 to be positioned before Epidiolex as a treatment option for Dravet Syndrome patients. He reiterates a Buy rating on Zogenix's shares.
IART Integra LifeSciences
$48.26

-0.83 (-1.69%)

10/31/17
UBSW
10/31/17
NO CHANGE
Target $57
UBSW
Buy
Integra LifeSciences pullback more than discounts disappointing report, says UBS
UBS analyst Matt Miksic noted Integra LifeSciences delivered disappointing Q3 results and lowered guidance, due partially to storm disruption and slower than expected performance in select product lines. The lowered guidance also takes into account management's slower underlying organic growth rate, which was offset by its Codman acquisition. The analyst still sees significant growth and leverage opportunities and views the pullback as more than discounting the disappointing execution. Miksic maintained his Buy rating and lowered his price target to $57 from $60 on Integra LifeSciences shares.
10/30/17
10/30/17
DOWNGRADE
Target $46

Market Perform
Integra LifeSciences downgraded to Market Perform at Wells Fargo
As previously reported, Wells Fargo analyst Larry Biegelsen downgraded Integra LifeSciences to Market Perform from Outperform after the company reported disappointing Q3 results. The analyst believes the recent organic growth "misses" suggest a lack of visibility, and notes that it is not clear what improves in Q4 despite management guiding to an improvement in organic growth. Additionally, Biegelsen says the key dural repair franchise continues to slow due to new competition, Omnigraft does not appear to have gotten traction in the market, the ortho extremities business is sub-scale, discontinued products are expected to continue to contribute to "organic" growth, 2018 appears to be a transition year once again, and upside potential from Codman accretion is less likely now given the investment in OTT. The analyst also lowered his price target on the shares to $46 from $56.
10/29/17
WELS
10/29/17
DOWNGRADE
WELS
Market Perform
Integra LifeSciences downgraded to Market Perform at Wells Fargo
10/27/17
JPMS
10/27/17
DOWNGRADE
Target $44
JPMS
Neutral
Integra LifeSciences downgraded to Neutral from Overweight at JPMorgan
JPMorgan analyst Robbie Marcus downgraded Integra LifeSciences to Neutral and lowered his price target for the shares to $44 from $58. Organic growth has slowed significantly over the past four quarter as multiple parts of the business have deteriorated, Marcus tells investors in a post-earnings research note. He lowered his growth outlook for the company following yesterday's Q3 results.
NVTA Invitae
$8.56

-0.14 (-1.61%)

08/04/17
LTCO
08/04/17
DOWNGRADE
LTCO
Neutral
CombiMatrix downgraded to Neutral from Buy at Ladenburg
Ladenburg Thalmann analyst Kevin Degeeter downgraded CombiMatrix (CBMX) to Neutral citing the takeover by Invitae (NVTA).
04/03/17
BNCH
04/03/17
NO CHANGE
Target $16
BNCH
Buy
Invitae price target raised to $16 from $11 at Benchmark
Benchmark analyst Raymond Myers noted that Invitae (NVTA) has contracted with Cigna (CI), Aetna (AET) and United Healthcare (UNH) over the past nine months to expand to 175M lives by year-end and following what may be some "short-term issues" he sees "exciting visibility" to an accelerating revenue outlook for the second half of 2017. Myers increased his price target on Invitae to $16 from $11 citing its substantial improvement in reimbursement and keeps a Buy rating on the shares.
05/08/17
05/08/17
NO CHANGE

Invitae reports Q1 EPS (64c), consensus (66c)
Reports Q1 revenue $10.3M, consensus $10.9M.
08/02/17
AGIS
08/02/17
NO CHANGE
Target $8.33
AGIS
Buy
CombiMatrix deal confusion presents arbitrage opportunity, says Aegis
Aegis analyst Benjamin Haynor noted that SEC filings related to the agreement for CombiMatrix (CBMX) to be acquired by Invitae (NVTA) present two formulas for the calculation of the exchange ratio, which he believes is causing some confusion, creating an arbitrage opportunity. He reiterates his Buy rating on CombiMatrix and raised his price target on the stock to $8.33 from $8.10, adding that the post-announcement rise in Invitae shares may make his target conservative if that move up holds.
MNK Mallinckrodt
$21.96

0.14 (0.64%)

11/22/17
11/22/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Salesforce (CRM) downgraded to Neutral from Buy at Roth Capital with analyst Richard Baldry citing the 59% year-to-date rally in the shares. 2. Bloomin' Brands (BLMN) downgraded to Neutral from Buy at BofA/Merrill with analyst Gregory Francfort citing news of Jana Partners' 8.7% stake and subsequent share price spike. 3. Halozyme (HALO) assumed with an Equal Weight from Overweight at Barclays with analyst Gena Wang saying she believes the potential of Halozyme's Enhanze technology is largely reflected in the stock following the recent rally. 4. Mallinckrodt (MNK) downgraded to Perform from Outperform at Oppenheimer with analyst Derek Archila saying he's been "flat out wrong" on the shares. 5. Cytokinetics (CYTK) was downgraded to Neutral from Overweight at Cantor Fitzgerald and to Buy from Strong Buy at Needham. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
11/14/17
ADAM
11/14/17
NO CHANGE
Target $24
ADAM
Hold
Mallinckrodt likely range-bound but insider buys encouraging, says Canaccord
Canaccord analyst Dewey Steadman noted Mallinckrodt shares are down over 40% since the beginning of October due to uncertainty surrounding unfilled prescriptions of its lead drug Acthar. The analyst noted recent management and board purchases of shares, which are encouraging, but he still thinks the shares will be range-bound around their current valuation. Steadman maintained his Hold rating and $24 price target on Mallinckrodt shares.
11/13/17
UBSW
11/13/17
DOWNGRADE
Target $24
UBSW
Neutral
Mallinckrodt downgraded to Neutral from Buy at UBS
UBS analyst Marc Goodman downgraded Mallinckrodt (MNK) to Neutral and cut his price target for the shares to $24 from $70. He sees the overhangs from slowing Acthar volumes and potential Praxair (PX) competition for INOmax persisting.
11/22/17
OPCO
11/22/17
DOWNGRADE
OPCO
Perform
Mallinckrodt downgraded to Perform from Outperform at Oppenheimer
Oppenheimer analyst Derek Archila downgraded Mallinckrodt to Perform saying he's been "flat out wrong" on the shares. The thesis of branded growth and material margin expansion has not and is unlikely to play out within the next 12-18 months, Archila tells investors in a research note. He sees "little-to-no visibility" on Acthar growth outside of management's remarks on the payer pushback/patient abandonment issues. Further, Archila is not certain whether the company can remedy the Acthar growth issue in a timely manner. He pulled his price target for Mallinckrodt shares.
MDT Medtronic
$79.87

-1.4 (-1.72%)

10/16/17
SBSH
10/16/17
NO CHANGE
Target $359.33
SBSH
Buy
TransEnterix not 'in the same league' as Intuitive Surgical, says Citi
Citi analyst Amit Hazan believes Friday's FDA approval of TransEnterix's (TRXC) Senhance Surgical Robotic System should be viewed far less in the context of a competitive threat to Intuitive Surgical's (ISRG) da Vinci and more of another sign that the FDA has "eased its bar" for approval. The TransEnterix Senhance system is "at least currently not in the same league as da Vinci," Hazan tells investors in a research note titled "Intuitive's First US Competitor Arrives, Sort Of." He admits, however, that Intuitive is increasingly likely to see new competition, from Medtronic (MDT) first and then Johnson & Johnson's (JNJ) joint venture "much later," on time or earlier than expected. Hazan still expects Intuitive to dominate, however, and keeps a Buy rating on the shares. The stock sold off 3% in after-hours trading on Friday following TransEnterix's announcement.
10/10/17
NEED
10/10/17
NO CHANGE
Target $94
NEED
Buy
Medtronic shares remain attractive despite hurricane impact, says Needham
Needham analyst Mike Matson lowered his price target on Medtronic to $94 from $95 to account for about $250M estimated negative impact from Puerto Rico manufacturing disruption due to Hurricane Maria. However, the analyst views the impact as temporary, maintaining his Buy rating given the large discount in stock price that Matson sees relative to peers. He also notes that reports of the company's "product cycle demise have been greatly exaggerated" and remains confident that Medtronic can sustain a mid-single digit revenue growth rate.
11/20/17
RHCO
11/20/17
NO CHANGE
Target $92
RHCO
Buy
Medtronic price target lowered to $92 from $96 at SunTrust
SunTrust analyst Bruce Nudell lowered his price target on Medtronic to $92 and kept his Buy rating. Nudell is modelling Q2 hurricane impact of about $59M relative to $55M-$65M guidance along with a less favorable FX adjustment of negative $18M. The analyst says he will monitor for an update on any expected residual storm impact for the rest of the year as well as any color on the company's new product pipeline.
10/10/17
BMOC
10/10/17
NO CHANGE
Target $89
BMOC
Outperform
BMO sees $250M impact on Medtronic from hurricane manufacturing disruption
BMO Capital analyst Joanne Wuensch lowered her price target for Medtronic to $89 from $92, modeling a $250M impact on manufacturing in Puerto Rico resulting from Hurricane Maria. Wuensch notes that most of the impact will occur in Q2 of FY18, also lowering her EPS target for the year to $4.63 from $4.78. The analyst kept her Outperform rating on the stock.
RICOY Ricoh Company, Ltd.

SUPN Supernus
$37.15

-0.05 (-0.13%)

11/07/17
RHCO
11/07/17
NO CHANGE
RHCO
Supernus should be bought on weakness, says SunTrust
11/07/17
STFL
11/07/17
UPGRADE
STFL
Buy
Supernus upgraded to Buy from Hold at Stifel
11/08/17
STFL
11/08/17
UPGRADE
Target $47
STFL
Buy
Supernus upgraded to Buy from Hold at Stifel
Stifel analyst Annabel Samimy upgraded Supernus Pharmaceuticals to Buy with a price target of $47 citing valuation. The analyst recommends buying the shares following yesterday's post-earnings weakness. Investor focus on the spike in gross-net in Q3 clouds the company's "stellar and consistent execution" and predictability in meeting expectations, Samimy tells investors in a research note after the shares fell 11%.
12/04/17
JANY
12/04/17
UPGRADE
Target $47
JANY
Buy
Supernus upgraded to Buy from Neutral at Janney Capital
Janney Capital analyst Ken Trbovich upgraded Supernus to Buy from Neutral, calling it the best positioned among the companies he covers to be an immediate beneficiary of lower U.S. corporate tax rates, which now appear highly likely for 2018 following the passage of tax bills in both the Senate and House. Reducing the Federal corporate tax rate from 35% to 22% would boost his 2018 EPS estimate for Supernus to $1.72 from $1.48 per share, noted Trbovich, who reiterated a $47 fair value estimate on the stock.
WTKWY Wolters Kluwer
$51.69

0.17 (0.33%)

03/10/17
GSCO
03/10/17
UPGRADE
GSCO
Neutral
Wolters Kluwer upgraded to Neutral from Sell at Goldman
ZBH Zimmer Biomet
$114.82

0.25 (0.22%)

11/07/17
RBCM
11/07/17
NO CHANGE
Target $125
RBCM
Outperform
Zimmer Biomet price target lowered to $125 from $140 at RBC Capital
RBC Capital analyst Glenn Novarro lowered his price target on Zimmer Biomet to $125 after Q3 earnings, saying the company continued to suffer from market share losses that were comparable to those of the first half as well the loss of business momentum in its S.E.T. division. Novarro is keeping his Outperform rating and urging investors to remain patient longer-term, with an update on CEO announcement before the end of the year and the re-inspection of the North Campus seen as catalysts toward regaining customer confidence and accelerating topline growth.
11/09/17
EDJN
11/09/17
UPGRADE
EDJN
Buy
Zimmer Biomet upgraded to Buy from Hold at Edward Jones
11/09/17
11/09/17
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Square (SQ) upgraded to Buy from Neutral at Guggenheim. 2. T-Mobile (TMUS) upgraded to Buy from Hold at Deutsche Bank with analyst Matthew Niknam saying his unchanged price target of $65 represents 17% upside. 3. NetApp (NTAP) upgraded to Overweight from Underweight at Barclays with analyst Mark Moskowitz saying he sees NetApp benefiting from market share gains in all-flash arrays and easing cloud-related headwinds over the next 6-12 months. 4. Cabot Oil & Gas (COG) upgraded to Buy from Hold at Drexel Hamilton with analyst Robert Christensen citing news the U.S. Court of Appeals for the District of Columbia has denied an emergency motion to stay the Federal Energy Regulatory Commission's authorization of the company's Atlantic Sunrise pipeline project, allowing construction to recommence. 5. Zimmer Biomet (ZBH) upgraded to Buy from Hold at Edward Jones. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
11/14/17
DBAB
11/14/17
UPGRADE
Target $128
DBAB
Buy
Zimmer Biomet upgraded to Buy from Hold at Deutsche Bank
Deutsche Bank analyst Kristen Stewart upgraded Zimmer Biomet to Buy and raised her price target for the shares to $128 from $126. The pending appointment of a CEO and some manufacturing improvements should drive improved sentiment around the stock following the recent pullback, Stewart tells investors in a research note.

TODAY'S FREE FLY STORIES

$DJT

DJ Transportation Average

08:21
12/14/17
12/14
08:21
12/14/17
08:21
Technical Analysis
DJ Transportation Average: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$DJU

DJ Utility Average

08:21
12/14/17
12/14
08:21
12/14/17
08:21
Technical Analysis
DJ Utility Average: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DJX

Dow Jones Industrial Average

08:21
12/14/17
12/14
08:21
12/14/17
08:21
Technical Analysis
Dow Jones Industrial Average: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SEMG

SemGroup

$27.35

0.2 (0.74%)

08:21
12/14/17
12/14
08:21
12/14/17
08:21
Upgrade
SemGroup rating change  »

SemGroup upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IYT

iShares Transportation Average

$187.87

0.54 (0.29%)

08:20
12/14/17
12/14
08:20
12/14/17
08:20
Technical Analysis
iShares Transportation Average: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XLK

Technology Select Sector SPDR

$64.15

0.02 (0.03%)

08:20
12/14/17
12/14
08:20
12/14/17
08:20
Technical Analysis
Technology Select Sector SPDR: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XLE

Energy Select Sector SPDR

$69.49

-0.1 (-0.14%)

08:20
12/14/17
12/14
08:20
12/14/17
08:20
Technical Analysis
Energy Select Sector SPDR: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XLY

Consumer Discretionary Sector SPDR

$97.58

0.08 (0.08%)

08:20
12/14/17
12/14
08:20
12/14/17
08:20
Technical Analysis
Consumer Discretionary Sector SPDR: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TEVA

Teva

$15.70

-0.82 (-4.96%)

08:19
12/14/17
12/14
08:19
12/14/17
08:19
Hot Stocks
Breaking Hot Stocks news story on Teva »

Teva says plans to pay…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Dec

FB

Facebook

$178.30

1.34 (0.76%)

, GOOG

Alphabet

$1,040.61

0.13 (0.01%)

08:19
12/14/17
12/14
08:19
12/14/17
08:19
Periodicals
MP criticizes Facebook after claims Russia spent just $1 on brexit ads, BI says »

Facebook (FB) has claimed…

FB

Facebook

$178.30

1.34 (0.76%)

GOOG

Alphabet

$1,040.61

0.13 (0.01%)

GOOGL

Alphabet Class A

$1,051.39

2.62 (0.25%)

TWTR

Twitter

$21.66

0.01 (0.05%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Jan

  • 07

    Feb

  • 18

    Mar

XLB

S&P Select Materials SPDR

$59.68

0.16 (0.27%)

08:19
12/14/17
12/14
08:19
12/14/17
08:19
Technical Analysis
S&P Select Materials SPDR: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DIOD

Diodes

$27.25

-0.32 (-1.16%)

08:19
12/14/17
12/14
08:19
12/14/17
08:19
Upgrade
Diodes rating change  »

Diodes upgraded to Buy on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Jan

XLU

Utilities SPDR

$55.40

0.15 (0.27%)

08:19
12/14/17
12/14
08:19
12/14/17
08:19
Technical Analysis
Utilities SPDR: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DIS

Disney

$107.61

0.18 (0.17%)

, FOX

21st Century Fox

$32.34

-1.26 (-3.75%)

08:19
12/14/17
12/14
08:19
12/14/17
08:19
Periodicals
Disney to pay $2.5B break up fee if 21st Century Fox deal stopped by regulators 

Reported by CNBC.

DIS

Disney

$107.61

0.18 (0.17%)

FOX

21st Century Fox

$32.34

-1.26 (-3.75%)

FOXA

21st Century Fox

$32.75

-1.35 (-3.96%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Dec

  • 14

    Dec

  • 14

    Dec

XLP

Consumer Staples Sector SPDR

$56.91

0.32 (0.57%)

08:19
12/14/17
12/14
08:19
12/14/17
08:19
Technical Analysis
Consumer Staples Sector SPDR: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XLV

Health Care Select Sector SPDR

$83.98

0.29 (0.35%)

08:18
12/14/17
12/14
08:18
12/14/17
08:18
Technical Analysis
Health Care Select Sector SPDR: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IWM

iShares Trust Russell 2000 Index Fund

$151.78

0.9 (0.60%)

08:18
12/14/17
12/14
08:18
12/14/17
08:18
Technical Analysis
iShares Trust Russell 2000 Index Fund: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DIA

Diamonds Fund ETF

$246.30

0.86 (0.35%)

08:18
12/14/17
12/14
08:18
12/14/17
08:18
Technical Analysis
Diamonds Fund ETF: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VMC

Vulcan Materials

$123.11

1.6 (1.32%)

08:17
12/14/17
12/14
08:17
12/14/17
08:17
Recommendations
Vulcan Materials analyst commentary  »

Vulcan Materials backlog…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPY

SPDR S&P 500 ETF Trust

$266.75

-0.03 (-0.01%)

08:17
12/14/17
12/14
08:17
12/14/17
08:17
Technical Analysis
SPDR S&P 500 ETF Trust: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DIS

Disney

$107.61

0.18 (0.17%)

, FOX

21st Century Fox

$32.34

-1.26 (-3.75%)

08:17
12/14/17
12/14
08:17
12/14/17
08:17
Hot Stocks
Breaking Hot Stocks news story on Disney, 21st Century Fox, 21st Century Fox »

Disney expects 21st…

DIS

Disney

$107.61

0.18 (0.17%)

FOX

21st Century Fox

$32.34

-1.26 (-3.75%)

FOXA

21st Century Fox

$32.75

-1.35 (-3.96%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Dec

  • 14

    Dec

  • 14

    Dec

LUV

Southwest

$63.14

-0.29 (-0.46%)

08:17
12/14/17
12/14
08:17
12/14/17
08:17
Upgrade
Southwest rating change  »

Southwest upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Dec

  • 15

    Dec

XLF

Financial Select Sector

$27.87

-0.35 (-1.24%)

08:17
12/14/17
12/14
08:17
12/14/17
08:17
Technical Analysis
Financial Select Sector: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CAG

Conagra Brands

$37.34

-0.21 (-0.56%)

, PF

Pinnacle Foods

$56.21

-0.49 (-0.86%)

08:17
12/14/17
12/14
08:17
12/14/17
08:17
Upgrade
Conagra Brands, Pinnacle Foods rating change  »

Conagra Brands upgraded…

CAG

Conagra Brands

$37.34

-0.21 (-0.56%)

PF

Pinnacle Foods

$56.21

-0.49 (-0.86%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Dec

SMH

Market Vectors Semiconductor

$97.69

0.06 (0.06%)

08:17
12/14/17
12/14
08:17
12/14/17
08:17
Technical Analysis
Market Vectors Semiconductor: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.